Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?

References

• Pui C-H, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547–547.
   PubMed Web of Science ®Google Scholar
• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.
   PubMed Web of Science ®Google Scholar
• Wolach O, Amitai I, DeAngelo DJ. Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia. Br J Haematol. 2017;179:705–723.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–950.
   PubMed Web of Science ®Google Scholar
• Vance KT, Kilgore ML, Yun H, et al. Race and non-Hodgkin’s lymphoma: adverse impact of race and treatment delays on survival. A SEER-Medicare Population Study (1995–2003). Blood. 2007;110:3578.
   Google Scholar
• Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–572.
   Web of Science ®Google Scholar
• Dahl J, Marx K, Jabbour E. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol. 2016;9:329–334.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52:325–327.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (New York, NY). 2008;321:974–977.
   Google Scholar
• Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493–1498.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017; 376:836–847.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Stelljes M, DeAngelo DJ, et al. Role of remission status and prior transplant in optimizing survival outcomes following allogeneic hematopoietic stem Transplantation (HSCT) in patients who received inotuzumab ozogamicin (INO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Blood. 2017;130:886.
   Google Scholar
• Song J, Ma Q, Gao W, et al. Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy. J Clin Oncol. 2018;36:e19000.
   Web of Science ®Google Scholar
• Kantarjian HM, Stein AS, Bargou RC, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer. 2016;122:2178–2185.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin. Oncol. 2017;35:1795–1802.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.
   PubMed Web of Science ®Google Scholar
• Advani AS, DeAngelo DJ, Marks DI, et al. Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): analysis from INO-VATE by bone marrow blast percentage (BMB%). J Clin Oncol. 2018;36:7028.
   Web of Science ®Google Scholar
• Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016:567–572.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522.
   PubMed Web of Science ®Google Scholar
• Maude SL, Teachey DT, Rheingold SR, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. J Clin Oncol. 2016; 34:3011–3011.
   Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–459.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4:e387–e398.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53:449–456.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4:230–234.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013; 119:2728–2736.
   PubMed Web of Science ®Google Scholar
• Maude SL, Pulsipher MA, Boyer MW, et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood. 2016;128:2801.
   Web of Science ®Google Scholar
• Lee KJ, Chow V, Weissman A, et al. Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults. Therapeut Clin Risk Manag. 2016;12:1301–1310.
   PubMed Web of Science ®Google Scholar
• Alfayez M, Kantarjian HM, Short NJ, et al. Safety and efficacy of blinatumomab in patients with central nervous system (CNS) disease: a single institution experience. Blood. 2018;132:2702.
   Web of Science ®Google Scholar
• Mahadeo KM, Khazal SJ, Abdel-Azim H, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16:45–63.
   PubMed Web of Science ®Google Scholar
• Novartis. KYMRIAH® (tisagenlecleucel) Efficacy Data & ELIANA CLinical Trial | HCP 2018 [cited 2018 Nov 14]. Available from: https://www.hcp.novartis.com/products/kymriah/acute-lymphoblastic-leukemia-children/efficacy/#patient-reported-qol
   Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–4140.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185–5187.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92:858–865.
   PubMed Web of Science ®Google Scholar
• Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Computat Struct Biotechnol J. 2016; 14:357–362.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Ogba N, Arwood NM, Bartlett NL, et al. Chimeric antigen receptor T-cell therapy. J Natl Compr Canc Netw. 2018;16:1092–1106.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1–14.
   Web of Science ®Google Scholar
• Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2019;33:884–892.
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381–4389.
   PubMed Web of Science ®Google Scholar
• Topp MS, Stelljes M, Zugmaier G, et al. Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. Leukemia. 2018;32:562–565.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Su Y, Jabbour EJ, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124:2151–2160.
   PubMed Web of Science ®Google Scholar
• Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20.
   PubMed Web of Science ®Google Scholar
• Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–3331.
   PubMed Web of Science ®Google Scholar
• Shah NN, Stetler-Stevenson M, Yuan CM, et al. Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Am Soc Hematol. 2016;128:650.
   Google Scholar
• Chahoud J, Kantarjian HM, Garcia-Manero G, et al. Outcome of patients with relapsed/refractory (R/R) acute lymphoid leukemia (ALL) after failure of inotuzumab ozogamicin. Blood. 2015;126:1298.
   Web of Science ®Google Scholar
• Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic leukemia: a phase 2 clinical Trial. Mini-HCVD and inotuzumab ozogamicin in relapsed or refractory ALL. JAMA Oncol. 2018;4:230–234.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Sasaki K, Ravandi F, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124:4044–4055.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1:1167–1180.
   PubMed Web of Science ®Google Scholar
• Stein A, Topp MS, Goekbuget N, et al. Allogeneic hematopoietic stem cell transplantation following anti-CD19 BiTE® blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Blood. 2014;124:965–965.
   Google Scholar
• Stein AS, Topp MS, Gokbuget N, et al. Outcomes of hematopoietic stem cell transplantation (HSCT) among adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) achieving remission with blinatumomab. Biol Blood Marrow Transplant. 2016;22:S35–S36.
   Google Scholar
• Zugmaier G, Gokbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126:2578–2584.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032–2041.
   PubMed Web of Science ®Google Scholar
• Terwey TH, Massenkeil G, Tamm I, et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant. 2008;42:791–798.
   PubMed Web of Science ®Google Scholar
• Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease. Relapse, and relapse-free survival. Bone Marrow Transplant. 1991;7:453–459.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Piantadosi S, Santos GW, et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol. 1990;8:820–830.
   PubMed Web of Science ®Google Scholar
• Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010;85:164–170.
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110:2309.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242–2249.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Hodgson JG, Shah NP, et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016;127:703.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–2088.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547–1555.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Dombret H, Chevallier P, et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA). Blood. 2015;126:679.
   Web of Science ®Google Scholar
• Assi R, Kantarjian H, Short NJ, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma, Myeloma Leuk. 2017;17:897–901.
   PubMed Web of Science ®Google Scholar
• Sokolov AN, Parovichnikova EN, Troitskaya VV, et al. Blinatumomab + tyrosine kinase inhibitors in the treatment of relapsed Philadelphia chromosome positive acute lymphoblastic leukemia patients – clinical efficacy and peripheral blood lymphocytes subpopulations kinetics. Blood. 2016;128:4024.
   Web of Science ®Google Scholar
• Stock W, Martinelli G, Stelljes M, et al. Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). J Clin Oncol. 2018;36:7030–7030.
   Web of Science ®Google Scholar
• Jain N, Cortes JE, Ravandi F, et al. Inotuzumab ozogamicin in combination with bosutinib for patients with relapsed or refractory Ph + ALL or CML in lymphoid blast phase. Blood. 2017;130:143.
   Web of Science ®Google Scholar
• Comber H, De Camargo Cancela M, Haase T, et al. Affluence and private health insurance influence treatment and survival in non-Hodgkin's lymphoma. PloS One. 2016;11:e0168684.
   PubMed Web of Science ®Google Scholar
• Stephan A, Grupp M, Shannon L, et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia. Oral abstract presented at: Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Improving Outcomes with Cellular Therapy. ASH Annual Meeting 2018, Ph.D. December 3, San Diego.
   Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–1518.
   PubMed Web of Science ®Google Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–2036.
   PubMed Web of Science ®Google Scholar
• Hay KA, Gauthier J, Hirayama AV, et al. Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells. J Clin Oncol. 2018;36:7005–7005.
   Google Scholar
• Liu J, Zhong JF, Zhang X, et al. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10:35.
   PubMed Web of Science ®Google Scholar
• Topp MS, Zimmerman Z, Cannell P, et al. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018;131:2906–2914.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer. 2018;9:1773–1781.
   PubMed Web of Science ®Google Scholar
• Dinner S, Liedtke M. Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2018;2018:9–15.
   PubMedGoogle Scholar
• Pulsipher MA. Are CAR T cells better than antibody or HCT therapy in B-ALL? Hematol Am Soc Hematol Educ Program. 2018;2018:16–24.
   PubMedGoogle Scholar
• Zhang X, X-a L, Yang J, et al. Efficacy and safety of CD19 chimeric antigen receptor (CAR) T cell therapy for B-cell acute lymphocytic leukemia (B-cell ALL) in a large cohort including patients with extramedullary disease (EMD), high leukemia burden, BCR-ABL (+) mutation, TP53 mutation, and post-transplant relapse. Blood. 2018;132:280.
   Web of Science ®Google Scholar
• Kantarjian HM, Stock W, Cassaday RD, et al. Comparison of CD22 expression between baseline, end of treatment, and relapse among patients treated with inotuzumab ozogamicin who responded and subsequently relapsed in two clinical trials. Blood. 2018;132:2699.
   Web of Science ®Google Scholar
• Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor–modified T cells: CD19 and the road beyond. Blood. 2018;131:2621.
   PubMed Web of Science ®Google Scholar
• Sboner A, Elemento O. A primer on precision medicine informatics. Brief Bioinform. 2016;17:145–153.
   PubMed Web of Science ®Google Scholar